Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROPEL
NCT04127578Phase 2Active, not recruiting
- Sponsor
- Prevail Therapeutics Inc.
- Start
- Jan 2020
- Primary completion
- Aug 2031
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 2
01
Overview
Phase 2, open-label trial of LY3884961 in Parkinson's disease (PD) (2 arms), sponsored by Prevail Therapeutics Inc. Primary endpoints: Cumulative number of Treatment-Emergent Adverse Events and Serious Adverse Events at 5 years, Incidence of procedure or treatment-emergent AEs measured by brain MRI, spine MRI and nerve conduction study at 5 years and 5 more. Started Jan 2020; status: active, not recruiting.
02
Drugs
LY3884961
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04127578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127578.